Stifel Financial’s Apellis Pharmaceuticals APLS Stock Holding History

Stifel Financial’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,220	Closed	-$1.14M	–	3708
2026 Q1	$1.14M	Sell	28,220 -8,441	-23%	-$182K	﹤0.01%	2380
2025 Q4	$921K	Buy	+36,661	New	+$860K	﹤0.01%	2500
2024 Q4	–	Sell	-27,641	Closed	-$797K	–	3381
2024 Q3	$797K	Sell	27,641 -2,682	-9%	-$99.3K	﹤0.01%	2378
2024 Q2	$1.16M	Buy	30,323 +8,600	+40%	+$389K	﹤0.01%	2070
2024 Q1	$1.28M	Buy	21,723 +1,807	+9%	+$115K	﹤0.01%	2039
2023 Q4	$1.19M	Sell	19,916 -10,118	-34%	-$513K	﹤0.01%	2022
2023 Q3	$1.14M	Buy	30,034 +12,016	+67%	+$528K	﹤0.01%	1965
2023 Q2	$1.64M	Buy	18,018 +1,300	+8%	+$112K	﹤0.01%	1766
2023 Q1	$1.1M	Buy	16,718 +9,508	+132%	+$549K	﹤0.01%	1982
2022 Q4	$373K	Buy	7,210 +558	+8%	+$29.6K	﹤0.01%	2637
2022 Q3	$454K	Buy	+6,652	New	+$394K	﹤0.01%	2480

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Stifel Financial's APLS Position: Q2 2026 in Review

Stifel Financial sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 28,220 shares — an estimated $1.14M sold.

Stifel Financial first reported a position in APLS in Q3 2022 and held it in 11 quarters. The position peaked at $1.64M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Stifel Financial reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Stifel Financial sold 28,220 Apellis Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
Stifel Financial first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 11 quarters.
Stifel Financial's Apellis Pharmaceuticals position peaked at $1.64M in Q2 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.